Navigation Links
Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM)
Date:8/2/2009

EAST BRUNSWICK, N.J., Aug. 2 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) stating that the FDA can not at this time approve the Company's Biologics License Application (BLA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy.

The complete response letter from the FDA cites deficiencies with the chemistry, manufacturing and controls (CMC) section of the BLA and also provided the current draft of the proposed labeling and further guidance regarding a Risk Evaluation and Mitigation Strategy (REMS) (Medication Guide and Communication Plan). The Company intends to immediately request a meeting with the FDA to discuss and clarify the issues raised in the complete response letter. Under FDA regulations, the Company believes that this meeting is deemed a "Type A" meeting, meaning that the FDA would meet with the Company within 30 days of its receipt of the meeting request.

One of the issues raised by the FDA in the complete response letter addresses a change made by the Company in the proposed process for manufacturing KRYSTEXXA for commercial use. The FDA has concluded that the comparability data submitted for the material manufactured using the proposed commercial manufacturing process was not adequate to demonstrate that it was representative of the material used to establish the safety and efficacy of KRYSTEXXA in its Phase 3 clinical trials. The FDA stated that the Company has the option of either reverting to and validating the manufacturing process used to produce KRYSTEXXA for the Phase 3 clinical trials or conducting additional comparability clinical trials to support the use of KRYSTEX
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. Savient Pharmaceuticals to Present at the Credit Suisse Phoenix Healthcare Conference on November 13th
2. Savients Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase
3. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
4. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results
5. Savient Pharmaceuticals to Present at The Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2010)... Reptiles are bred in captivity primarily for their skins, ... for their meat. A study shows that eating these ... the wisdom of eating this ,delicacy., , Parasites, bacteria ... heavy metals and residues of veterinary drugs- eating reptile ... the conclusion of a study published in the ...
(Date:2/9/2010)... Idaho Lose $1.6 Billion from Feds & Thousands ... 9 As the Idaho House approved legislation ... care law, the long-term effects of the move could be ... Health Freedom Act (House Bill 391) a disastrous and problem-riddled ... Idaho lose nearly $1.6 billion in ...
(Date:2/9/2010)... Michigan State University has launched the nation,s first ... product counterfeiting- which the FBI has called "the ... of products- from pharmaceuticals to food additives to ... dollars in global trade and has a major ... environment and national security. Terrorist and other organized ...
(Date:2/9/2010)... born prematurely in the US, according to data presented ... findings were reported at the 30th Annual Meeting of ... were published in the latest issue of the ... reported that CP is associated with inflammation of the ... more common in premature births from preterm labor and ...
(Date:2/9/2010)... Feb. 9 The following is a ... ,, "Reversing the childhood obesity epidemic will require the ... demonstrated today. ,, "As the First Lady ... with chips and soda -- and few healthy food ... bleak food landscape extends far beyond the school yard. ...
Breaking Medicine News(10 mins):Health News:Study carried out into biological risks of eating reptiles 2Health News:Idaho House Moves State Closer to Health Care Disaster 2Health News:Idaho House Moves State Closer to Health Care Disaster 3Health News:Idaho House Moves State Closer to Health Care Disaster 4Health News:MSU launches first anti-counterfeiting research program 2Health News:MSU launches first anti-counterfeiting research program 3Health News:Incidence of cerebral palsy on rise in US 2
... is improved by incorporation of folic acid in the diet, ... that folic acid supplementation during pregnancy can reduce the incidence ... ,The researchers analyzed the effect of consumption of ... spina bifida between the year 1998 and 2001. 92% of ...
... on high alert after it was confirmed that the dreaded bird ... after it was confirmed that a cat had died of bird ... to ward off the disease. // Federal Agriculture and Protection of ... of the bird flu will be kept inside homes, while it ...
... Ontario and followed over two years, researchers found that only 66 ... author of the study by the Institute of Clinical Evaluative Sciences ... around 19 times in two years. It was later found that ... are not keeping good health and are not going in for ...
... the ban on smoking in public places to be enforced, a ... habit for good on the National No Smoking Day. // ... nearly 6.3 million in the UK have died due to smoking. ... organizers, nearly 41 per cent of smokers - around five million ...
... London has decided to offer free fertility treatment to unmarried ... free pilot scheme has been initiated just in time,// before ... ,Although many fell that the move would destabilize traditional ... it could mean the ultimate in women liberation. There has ...
... follow-up of a TB case in Aberdeen. ,Six people ... heath officials are reassuring the public, not to worry. // ... contact with all those who attended Friday prayers at Aberdeen City ... the doctors say that the six patients who were diagnosed with ...
Other Medicine News:Health News:Vaccination Schedules Rates among Canadian Kids Dip Low 2
(Date:2/9/2010)... , Feb. 9 Palatin ... announced the completion of first cohort dosing in ... experimental treatment for sexual dysfunction.  The primary endpoint ... blood pressure effects of subcutaneous bremelanotide in men ... will also evaluate consistency of plasma exposure of ...
(Date:2/9/2010)... February 9 Debiopharm Group,(Debiopharm), ... with,a focus on the development of prescription ... the signature of an exclusive licence agreement ... of Debio 025,(alisporivir), a selective, first-in-class cyclophilin ... (HCV) effect. The product is currently in ...
(Date:2/8/2010)... PreXion, Inc., ( www.prexion.com ) ... systems for dentistry, today announced that it has appointed ... ,, PreXion President/COO Robert Meier commented, "We ... team and I look forward to working with him ... experience and success in the dental and high tech ...
Breaking Medicine Technology:Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men 2Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men 3Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men 4Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 2Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 3PreXion, Inc. Announces Appointment of Director of Marketing 2UNC study pinpoints gene controlling number of brain cells 10250 1UNC study pinpoints gene controlling number of brain cells 10250 2Care Workers Key Members of Interdisciplinary Health Care Team 58825 1Care Workers Key Members of Interdisciplinary Health Care Team 58825 2Mercy Ships Surgeon Addresses Blindness Through Sutureless Technique 58822 1Mercy Ships Surgeon Addresses Blindness Through Sutureless Technique 58822 2Mercy Ships Surgeon Addresses Blindness Through Sutureless Technique 58822 3Mercy Ships Surgeon Addresses Blindness Through Sutureless Technique 58822 4
... 2007 (BUSINESS WIRE) -- MGI PHARMA, INC.,(NASDAQ:MOGN), ... care, today announced the presentation of results ... Aquavan(R) (fospropofol,disodium) Injection in patients undergoing colonoscopy. ... as safety data, were,presented at Digestive Disease ...
... * Ozarelix Effective in Improving Symptoms and Urine ... IRVINE, Calif., May 23, 2007 /PRNewswire-FirstCall/ -- Spectrum,Pharmaceuticals, ... for ozarelix, the Company's drug candidate for the ... Urology,Association Annual Meeting held at the Anaheim Convention ...
Other Medicine Technology:Aquavan (Fospropofol Disodium) Injection Data Presented at,Digestive Disease Week 2007 2Aquavan (Fospropofol Disodium) Injection Data Presented at,Digestive Disease Week 2007 3Aquavan (Fospropofol Disodium) Injection Data Presented at,Digestive Disease Week 2007 4Aquavan (Fospropofol Disodium) Injection Data Presented at,Digestive Disease Week 2007 5Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 2Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 3Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 4Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 5
... Delivery System incorporates a translucent inner sleeve ... confidence that each needle load matches the ... other preloaded needle options, the IsoSleeve™ system ... configuration giving you confidence that the needle ...
... The Quinton Q-Track II Holter Monitoring ... company that produced the worlds first true ... true 12-lead presentation of any beat contained ... segment analysis. , ,The preprocessing work done ...
... been designed as a compact, cost-effective and ... private clinics or as a second system. ... most commonly required investigations such as Uroflowmetry, ... Add-on options are available for Urethral Pressure ...
A compact mobile System Cart gives mobility within your department. The cart accomodates the Uromac Median data processor, desktop computer, printer and provides stowage space. Patient related transd...
Medicine Products: